Summary
Serotonin (5-hydroxytryptamine, 5-HT) is one of the most consistently implicated neurotransmitter systems in autism, yet no single serotonin-based explanation of autism has been established. The evidence is accumulating from multiple directions — genetics, blood markers, receptor studies, pharmacological probing — but has not yet converged into a definitive account. This page collects what is known and flags what is under active investigation.
This is tagged status/draft because the page depends heavily on the PSILAUT trial results (see Whelan et al. 2024 — PSILAUT), which are not yet published. When those results arrive, this page should be substantially updated.
What the evidence shows
Genetic associations
Polymorphisms in genes for serotonin synthesis (TPH2), the serotonin transporter (SLC6A4/SERT), and serotonin receptors (especially HT2RA, the gene for the 5HT₂A receptor) are associated with autism in various studies. None is a single causal gene — the associations are probabilistic and of small effect.
Blood serotonin
Elevated whole-blood serotonin levels are reported in roughly one-third of autistic individuals. This was one of the first biological findings in autism research (Schain & Freedman, 1961) and remains among the most replicated. Its meaning is debated — peripheral serotonin and central serotonin are largely separate systems, so what whole-blood levels tell us about brain function is unclear.
The 5HT₂A receptor
This receptor is of special interest because it sits at the intersection of several processes relevant to autism:
- Developmental role: 5HT₂A is involved in dendritic maturation, neuronal differentiation, and regulation of brain-derived neurotrophic factor (BDNF) during development. Early perturbations in 5HT₂A signalling may shape subsequent brain architecture.
- Location: 5HT₂A receptors are densely expressed in sensorimotor integration regions and in the default mode network (DMN) — exactly the areas implicated in both sensory processing differences and self-referential processing in autism.
- Binding studies: Lower cortical 5HT₂A receptor binding has been correlated with social communication differences in autism, though the evidence is correlational rather than causal.
- Pharmacological action: The 5HT₂A receptor is the principal (though not exclusive) target of psilocybin and other classic psychedelics. This makes psilocybin a natural pharmacological probe for the receptor’s function — which is the basis of the PSILAUT study.
Prior pharmacological evidence
The PSILAUT team’s earlier work used the SSRI citalopram (which broadly elevates serotonin) to show that acute serotonin elevation differentially affects autistic brain function: sustained activation in face-processing regions in autistic adults but not controls. This was a proof of concept for the “shiftability” approach — manipulate the system, observe a differential response.
The excitation-inhibition (E/I) balance connection
5HT₂A receptor signalling increases cortical glutamate and thalamic GABA levels, i.e. it influences the balance between excitatory and inhibitory neurotransmission. E/I imbalance is independently proposed as a contributor to sensory processing differences in autism. The serotonin system may be one of the upstream regulators of that balance.
The predictive processing connection
Under the predictive processing framework (see Predictive processing and autism), 5HT₂A receptor function is hypothesised to modulate the precision weighting of priors versus sensory evidence. The REBUS model proposes that 5HT₂A stimulation reduces the precision of high-level priors (relaxing beliefs). If this receptor functions differently in autistic brains — which is what PSILAUT is designed to test — it could be part of the mechanism by which autistic brains assign different weights to prediction errors.
Open questions
- Does the 5HT₂A pathway function differently in autistic versus non-autistic brains? This is the PSILAUT question. No study has yet directly tested functional differences; all prior evidence is correlational or genetic.
- What about autistic people with intellectual disability? PSILAUT excludes this population for ethical and practical reasons. Whether serotonin system differences apply beyond the adult-without-ID population is unknown.
- Is peripheral serotonin elevation causally meaningful? Or is it an epiphenomenon of a shared upstream process?
- How does 5HT₂A interact with other serotonin receptors? Psilocin binds at least seven other serotonin receptor subtypes. The specificity of any finding to 5HT₂A will need careful disentangling.
Implications for practice (tentative)
The serotonin evidence is not yet actionable at the level of daily care. What it does is deepen the why behind sensory processing differences — moving from “this person’s brain processes stimuli differently” to “this person’s brain may be assigning different weights to sensory evidence because of the way their serotonin system modulates cortical gain.” That deeper understanding does not change the recommendation to build individual stimulus profiles and maintain prikkelbalans, but it strengthens the theoretical grounds for those practices.
Key sources
- Whelan et al. 2024 — PSILAUT — the study protocol that will provide the first direct evidence
- Roseby & Osborn Moar 2025 — Predictive processing as a lens on psychedelics and autism — the theoretical framework
- Schain, R.J., & Freedman, D.X. (1961). Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. The Journal of Pediatrics, 58(3), 315–320.
- Carhart-Harris, R.L., & Friston, K.J. (2019). REBUS and the anarchic brain. Pharmacological Reviews, 71(3), 316–344.